Jaketrius Lurry, et al. v. PharMerica Corporation

CourtDistrict Court, W.D. Kentucky
DecidedJune 29, 2026
Docket3:23-cv-00297
StatusUnknown

This text of Jaketrius Lurry, et al. v. PharMerica Corporation (Jaketrius Lurry, et al. v. PharMerica Corporation) is published on Counsel Stack Legal Research, covering District Court, W.D. Kentucky primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jaketrius Lurry, et al. v. PharMerica Corporation, (W.D. Ky. 2026).

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF KENTUCKY LOUISVILLE DIVISION

JAKETRIUS LURRY, et al., Plaintiff

v. Civil Action Lead Case No. 3:23-cv-297-RGJ

PHARMERICA CORPORATION, Defendants

MEMORANDUM OPINION & ORDER

Plaintiffs David Hibbard, Frank Raney, James Young, Holly Williams, Micaela Molina, and Charley Luther (“Plaintiffs”) request that the Court grant final approval of the nationwide class action settlement with Defendant PharMerica Corporation (“PharMerica”), and for attorneys’ fees, expenses, and class representative service awards. [DE 156]. PharMerica does not oppose Plaintiffs’ motion. The Court received a letter from Class Member John Bosk. [DE 157]. A Final Approval Hearing1 was held on May 12, 2026. [DE 162]. Pursuant to the Court’s order at the Final Approval Hearing, Plaintiffs filed supplemental briefing on June 2, 2026. [DE 164]. This matter is ripe. For the following reasons, Plaintiffs’ motion [DE 156] is GRANTED. I. BACKGROUND PharMerica is a pharmacy services provider for various healthcare facilities and programs nationwide. [DE 38 at 506]. PharMerica collects and maintains personal identifiable information (“PII”) and protected health information (“PHI”) (collectively, “personal information”) of its

1 The Settlement Agreement is attached as Exhibit A to Plaintiffs’ unopposed motion. [DE 146- 1]. All capitalized terms not otherwise defined herein shall have the same meaning ascribed to them in the Settlement Agreement. [See, e.g., id. (“‘Final Approval Hearing’ means the hearing held before the Court during which the Court will consider granting Final Approval of the Settlement and the Application for Attorneys’ Fees, Costs, and Service Awards.”)]. 1 clients’ patients and employees. [Id. at 507]. Plaintiffs allege that in March 2023 a cybercriminal ransomware gang targeted PharMerica’s computer network and exfiltrated 4.7 terabytes of information, including Plaintiffs’ personal information (the “Data Incident”). [DE 146 at 983–83]. Thereafter, Plaintiffs filed their individual complaints, which were consolidated into the instant matter on July 19, 2023. [DE 20].

On October 16, 2023, after reviewing multiple competing motions for appointment, this Court entered an order appointing J. Gerard Stranch, IV of Stranch, Jennings, & Garvey, PLLC as Interim Lead Counsel, E. Michelle Drake of Berger Montague, P.C., Gary M. Klinger of Milberg Coleman Phillips Grossman, PLLC, and Lynn A. Toops of CohenMalad, LLP, as Executive Committee Co-Members, and August Herbert of Gray Ice Higdon as Liaison Counsel. [DE 31]. On November 30, 2023, Plaintiffs filed their Consolidated Class Action Complaint. [DE 33]. Subsequently, on January 12, 2024, Plaintiffs filed their First Amended Consolidated Class Action Complaint. [DE 38]. On June 12, 2024, the Court granted in part and denied in part PharMerica’s motion to

dismiss. [DE 46]. Shortly thereafter, the parties exchanged informal discovery regarding the Data Incident, including details as to how the incident occurred, who was involved, the specific data elements impacted, liability, and damages. [DE 146 at 983–84]. Then, on August 1, 2025, the parties engaged in formal mediation which resulted in an agreement to settle. [Id. at 984]. Over the next several weeks, the parties finalized the Settlement Agreement, including by working with Kroll Settlement Administration, LLC (“Kroll” or the “Settlement Administrator”), to create the Notice Program and Notices, and to formulate the Claims Process and draft the Claim Form. [Id.].

2 A. Settlement Agreement 1. The Settlement Class Under the Settlement Agreement, the Settlement Class is defined as “all living persons in the United States who were provided notice of the Data Incident.” [DE 146-1 ¶ 59]. Excluded from the Settlement Class are:

[A]ll persons who are directors and officers of Defendant, governmental entities, anyone who validly and timely opts out of the Settlement, and the judge(s) assigned to the Action, the Judge’s immediate family, and Court staff. [Id.] Any Class Members, as defined above, will have until thirty (30) days before the initial scheduled Final Approval Hearing to opt out of the Settlement. [Id. ¶ 46]. 2. Settlement Benefits The Settlement Agreement creates two funds: a Settlement Fund and a Claims-Made Fund. First, PharMerica shall pay $5,275,000.00 into a non-reversionary fund (the “Settlement Fund”). Following the payment of: (1) all Settlement Administration Costs, (2) PharMerica’s past and future costs of data mining to confirm membership in the Settlement Class; (3) any Service Awards awarded to Class Representatives; and (4) attorneys’ fees and costs as awarded to Class Counsel, the Settlement Fund will provide Class Members with the ability to claim a cash payment that will be increased or decreased on a pro rata basis. [DE 146-1 ¶¶ 65-66, 70(b)]. In addition to the Settlement Fund, PharMerica will pay claims for documented out-of- pocket expenses up to $10,000 per Class Member and one year of Kroll Complete Monitoring on a claims-made basis (the “Claims-Made Fund”). [Id. ¶¶ 70-71]. Kroll Complete Monitoring includes credit monitoring, dark web monitoring, pay day loan monitoring, social security scan, fraud consultation, identity theft restoration services (including victim assistance and customer support), $1,000,000 of insurance coverage for fraud and/or identity theft with no deductible, credit

3 score reporting, and real-time inquiry alerts. [Id. ¶ 71]. Class Members will have until fifteen (15) days before the initial scheduled Final Approval Hearing to submit a claim. [Id. ¶ 55]. Lastly, the Settlement Agreement provides that PharMerica has adopted, paid for, implemented, and will maintain certain “Business Practice Changes” related to information security to safeguard personal information on its systems. [Id. ¶ 72.]

3. Notice Program Within 14 days of preliminary approval, PharMerica will provide Kroll with a list of Class Members. [DE 146 at 986]. Kroll will administer the Notice Program by sending Email Notices and/or Postcard Notices, depending on the type of information maintained by PharMerica. [Id.]. Pursuant to the Settlement Agreement, The Notice shall include a description of the material terms of the Settlement; how to submit a Claim Form; the Claim Form Deadline; the Opt-Out Deadline for individuals in the Settlement Class to opt-out of the Settlement Class; the Objection Deadline for Settlement Class Members to object to the Settlement and/or the Application for Attorneys’ Fees, Costs, and Service Awards; the Final Approval Hearing date; and the Settlement Website address at which Settlement Class Members may access [the Settlement] Agreement and other related documents and information. Kroll will also establish a Settlement Website to provide Class Members with all relevant information and documents, including the Settlement Agreement, Claims and Notice Forms, and Court orders. Moreover, Kroll will perform reasonable address trace efforts for any Postcards that are returned as undeliverable. [Id. (citation modified)]. Class Members wishing to opt-out will be required to postmark their request to Kroll. Class Members with objections must “must mail a letter to the Clerk of the Court, Class Counsel, Defendant’s Counsel, and the Settlement Administrator,” containing certain information as set forth in the Settlement Agreement. [Id. at 987 (listing nine criteria required to be addressed in objection letter)]. 4 4. Fees, Expenses, and Service Awards Under the Settlement Agreement, Class Counsel will apply to the Court for an award of attorneys’ fees of “up to $3,481,750.00, which equates to 33% of the Settlement Fund and significantly less than one-third of the value of Cash Payment A – Documented Losses, and Credit Monitoring, made available through the Settlement.” [Id. at 988].

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Strong v. Bellsouth Telecommunications Inc.
137 F.3d 844 (Fifth Circuit, 1998)
Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Ellison v. Balinski
625 F.3d 953 (Sixth Circuit, 2010)
Bowling v. Pfizer, Inc.
102 F.3d 777 (Sixth Circuit, 1996)
In the Matter Of: Synthroid Marketing Litigation
264 F.3d 712 (Seventh Circuit, 2001)
Everett Hadix, C. Pepper Moore v. Perry Johnson
322 F.3d 895 (Sixth Circuit, 2003)
Philecia Barnes v. City of Cincinnati
401 F.3d 729 (Sixth Circuit, 2005)
Moulton v. United States Steel Corp.
581 F.3d 344 (Sixth Circuit, 2009)
In Re TJX Companies Retail Security Breach Litigation
584 F. Supp. 2d 395 (D. Massachusetts, 2008)
Lonardo v. Travelers Indemnity Co.
706 F. Supp. 2d 766 (N.D. Ohio, 2010)
Shannon Van Horn v. Nationwide Property and Casualty
436 F. App'x 496 (Sixth Circuit, 2011)
Amber Gascho v. Global Fitness Holdings, LLC
822 F.3d 269 (Sixth Circuit, 2016)
Vicki Linneman v. Vita-Mix Corp.
970 F.3d 621 (Sixth Circuit, 2020)
Shiyang Huang v. Equifax Inc.
999 F.3d 1247 (Eleventh Circuit, 2021)
In re Cardizem CD Antitrust Litigation
218 F.R.D. 508 (E.D. Michigan, 2003)
Thacker v. Chesapeake Appalachia, L.L.C.
259 F.R.D. 262 (E.D. Kentucky, 2009)
Wayside Church v. Van Buren Cnty., Mich.
103 F.4th 1215 (Sixth Circuit, 2024)
Dennis Speerly v. General Motors, LLC
143 F.4th 306 (Sixth Circuit, 2025)

Cite This Page — Counsel Stack

Bluebook (online)
Jaketrius Lurry, et al. v. PharMerica Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jaketrius-lurry-et-al-v-pharmerica-corporation-kywd-2026.